• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Starboard Value Issues Presentation Delivered at 13D Monitor's 2024 Active-Passive Investor Summit

    10/22/24 8:55:00 AM ET
    $CRM
    $KVUE
    $PFE
    Computer Software: Prepackaged Software
    Technology
    Specialty Chemicals
    Consumer Discretionary
    Get the next $CRM alert in real time by email

    Starboard Value LP (together with its affiliates, "Starboard" or "we"), today announced that Jeffrey Smith, the firm's Chief Executive Officer and Chief Investment Officer, delivered a presentation at the 2024 Active-Passive Investor Summit to highlight value creation opportunities at three companies: Kenvue Inc. (NYSE:KVUE), Pfizer Inc. (NYSE:PFE) and Salesforce Inc. (NYSE:CRM). The full presentation and the respective presentations for the aforementioned companies can be found at: https://www.starboardvalue.com/presentations.

    About Starboard Value LP

    Starboard Value LP is an investment adviser with a focused and differentiated fundamental approach to investing in publicly traded companies. Starboard invests in deeply undervalued companies and actively engages with management teams and boards of directors to identify and execute on opportunities to unlock value for the benefit of all shareholders.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20241022671573/en/

    Get the next $CRM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CRM
    $KVUE
    $PFE

    CompanyDatePrice TargetRatingAnalyst
    Pfizer Inc.
    $PFE
    3/2/2026$35.00Hold → Buy
    Argus
    Salesforce Inc.
    $CRM
    2/26/2026$235.00 → $225.00Outperform
    BMO Capital Markets
    Pfizer Inc.
    $PFE
    2/25/2026$25.00Underperform
    RBC Capital Mkts
    Pfizer Inc.
    $PFE
    2/20/2026$25.00Underweight
    Barclays
    Salesforce Inc.
    $CRM
    2/20/2026$275.00 → $235.00Outperform
    BMO Capital Markets
    Pfizer Inc.
    $PFE
    2/12/2026$27.00Outperform → Neutral
    Daiwa Securities
    Kenvue Inc.
    $KVUE
    1/30/2026$18.00Buy → Hold
    Jefferies
    Salesforce Inc.
    $CRM
    1/12/2026$330.00Buy
    Goldman
    More analyst ratings

    $CRM
    $KVUE
    $PFE
    SEC Filings

    View All

    Salesforce Inc. filed SEC Form 8-K: Leadership Update

    8-K - Salesforce, Inc. (0001108524) (Filer)

    3/6/26 4:15:12 PM ET
    $CRM
    Computer Software: Prepackaged Software
    Technology

    SEC Form 10-K filed by Salesforce Inc.

    10-K - Salesforce, Inc. (0001108524) (Filer)

    3/2/26 4:24:59 PM ET
    $CRM
    Computer Software: Prepackaged Software
    Technology

    SEC Form 10-K filed by Pfizer Inc.

    10-K - PFIZER INC (0000078003) (Filer)

    2/26/26 12:44:01 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRM
    $KVUE
    $PFE
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 25, 2024 - FDA Roundup: October 25, 2024

    For Immediate Release: October 25, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA updated the advisory for the outbreak of E. coli O157:H7. A specific ingredient has not yet been confirmed as the source of the outbreak, but most sick people report eating McDonald’s Quarter Pounder burgers. Investigators are working to deter

    10/25/24 2:48:21 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for HYMPAVZI issued to PFIZER INC

    Submission status for PFIZER INC's drug HYMPAVZI (ORIG-1) with active ingredient MARSTACIMAB-HNCQ has changed to 'Approval' on 10/11/2024. Application Category: BLA, Application Number: 761369, Application Classification:

    10/15/24 2:57:27 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    October 11, 2024 - FDA Approves New Treatment for Hemophilia A or B

    For Immediate Release: October 11, 2024 Today, the U.S. Food and Drug Administration approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors (neutralizing antibodies). “Today’s approval of Hympavzi pro

    10/11/24 2:12:15 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRM
    $KVUE
    $PFE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Pfizer upgraded by Argus with a new price target

    Argus upgraded Pfizer from Hold to Buy and set a new price target of $35.00

    3/2/26 8:00:47 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BMO Capital Markets reiterated coverage on Salesforce with a new price target

    BMO Capital Markets reiterated coverage of Salesforce with a rating of Outperform and set a new price target of $225.00 from $235.00 previously

    2/26/26 6:51:04 AM ET
    $CRM
    Computer Software: Prepackaged Software
    Technology

    RBC Capital Mkts initiated coverage on Pfizer with a new price target

    RBC Capital Mkts initiated coverage of Pfizer with a rating of Underperform and set a new price target of $25.00

    2/25/26 7:53:28 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRM
    $KVUE
    $PFE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Group President EMEA & LA Lawson Carlton converted options into 7,736 shares, increasing direct ownership by 8% to 105,257 units (SEC Form 4)

    4 - Kenvue Inc. (0001944048) (Issuer)

    3/9/26 5:03:16 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Chief People Officer Alvarado Luani converted options into 4,289 shares and covered exercise/tax liability with 2,094 shares, increasing direct ownership by 4% to 59,271 units (SEC Form 4)

    4 - Kenvue Inc. (0001944048) (Issuer)

    3/9/26 5:03:05 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Chief Operations Officer Stevens Meredith converted options into 6,178 shares and covered exercise/tax liability with 1,677 shares, increasing direct ownership by 5% to 90,547 units (SEC Form 4)

    4 - Kenvue Inc. (0001944048) (Issuer)

    3/9/26 5:02:57 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    $CRM
    $KVUE
    $PFE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Pfizer's Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis

    Study met primary endpoint, demonstrating statistically significant increase in the percentage of participants achieving EASI-75 at Week 16 across all doses tested, compared to placebo Tilrekimig (PF-07275315) was well-tolerated with a favorable safety profile Tilrekimig has the potential to be a first-in-class, once-monthly trispecific antibody targeting interleukin-4 (IL-4), interleukin-13 (IL-13), and thymic stromal lymphopoietin (TSLP) for multiple chronic Type 2 (Th2) inflammatory conditions including atopic dermatitis, asthma, and chronic obstructive pulmonary disease (COPD) Based on encouraging results, Pfizer plans to accelerate tilrekimig to Phase 3 development, with a pi

    3/9/26 6:45:00 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NYSE Content Update: Alysa Liu Rings NYSE Bell After Winning Two Gold Medals

    NYSE issues a pre-market daily advisory direct from the trading floor.NEW YORK, March 4, 2026 /CNW/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins.  Ashley Mastronardi delivers the pre-market update on March 4thEquities are volatile amid the ongoing conflict in the Middle East, with President Trump saying late Tuesday that the U.S. will provide risk insurance to all maritime trade in the Persian Gulf.Two-time Olympic gold-medalist figure skater Alysa Liu joined Kristen Scholer for an interview from the Rink at Rockefeller

    3/4/26 8:55:00 AM ET
    $ICE
    $PFE
    $SMWB
    Investment Bankers/Brokers/Service
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ParaZero Strengthens Global Sales Leadership with Appointment of Bat-Sheva Noy as VP

    Kfar Saba, Israel, March 04, 2026 (GLOBE NEWSWIRE) -- ParaZero Technologies Ltd. (NASDAQ:PRZO) (the "company" or "ParaZero"), an aerospace defense company pioneering smart, autonomous solutions for the global manned and unmanned aerial systems (UAS) industry, recently announced the appointment of Bat-Sheva Noy as its new Vice President of Global Sales. Ms. Noy brings more than 20 years of extensive commercial and leadership experience, with particular expertise in strategic planning, market access, and leading cross-functional teams. Most recently, from 2020 to 2025, she served as the Business Unit Lead for Rare Diseases at Pfizer Israel ((a subsidiary of Pfizer Inc., NYSE:PFE). In that

    3/4/26 8:32:00 AM ET
    $PFE
    $PRZO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Military/Government/Technical
    Industrials

    $CRM
    $KVUE
    $PFE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kirk David Blair bought $500,722 worth of shares (1,936 units at $258.64), increasing direct ownership by 22% to 10,677 units (SEC Form 4)

    4 - Salesforce, Inc. (0001108524) (Issuer)

    12/18/25 5:10:12 PM ET
    $CRM
    Computer Software: Prepackaged Software
    Technology

    Director Smith Jeffrey C bought $110,986,526 worth of shares (6,377,694 units at $17.40) (SEC Form 4)

    4 - Kenvue Inc. (0001944048) (Issuer)

    12/15/25 4:00:25 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Director Morfit G Mason bought $25,015,680 worth of shares (96,000 units at $260.58) (SEC Form 4)

    4 - Salesforce, Inc. (0001108524) (Issuer)

    12/8/25 9:30:14 AM ET
    $CRM
    Computer Software: Prepackaged Software
    Technology

    $CRM
    $KVUE
    $PFE
    Leadership Updates

    Live Leadership Updates

    View All

    ParaZero Strengthens Global Sales Leadership with Appointment of Bat-Sheva Noy as VP

    Kfar Saba, Israel, March 04, 2026 (GLOBE NEWSWIRE) -- ParaZero Technologies Ltd. (NASDAQ:PRZO) (the "company" or "ParaZero"), an aerospace defense company pioneering smart, autonomous solutions for the global manned and unmanned aerial systems (UAS) industry, recently announced the appointment of Bat-Sheva Noy as its new Vice President of Global Sales. Ms. Noy brings more than 20 years of extensive commercial and leadership experience, with particular expertise in strategic planning, market access, and leading cross-functional teams. Most recently, from 2020 to 2025, she served as the Business Unit Lead for Rare Diseases at Pfizer Israel ((a subsidiary of Pfizer Inc., NYSE:PFE). In that

    3/4/26 8:32:00 AM ET
    $PFE
    $PRZO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Military/Government/Technical
    Industrials

    Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

    Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham

    1/8/26 4:30:00 PM ET
    $ARVN
    $DGX
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Biotechnology: Laboratory Analytical Instruments

    Pfizer Reaches Landmark Agreement with U.S. Government to Lower Drug Costs for American Patients

    Voluntary agreement meets the President's four requests while also protecting the U.S. ecosystem responsible for America's leadership in delivering medical breakthroughs Agreement provides certainty from tariffs and clarity on pricing framework that furthers Pfizer's ability to expand investment in U.S.-based innovation and return manufacturing to the U.S. Pfizer to fully focus on delivering the next generation of cures, especially in cancer, obesity, vaccines, and inflammation and immunology Pfizer CEO Albert Bourla joins President Donald J. Trump and members of his Administration in White House event today Pfizer Inc. (NYSE:PFE) today announced a historic agreement with the T

    9/30/25 12:45:00 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRM
    $KVUE
    $PFE
    Financials

    Live finance-specific insights

    View All

    Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

    Pfizer Inc. (NYSE:PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 10:30 a.m. EST. To listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. The transcript and webcast replay of the discussion will be made available on our web site at www.pfizer.com/investors within 24 hours after the end of the live discussion and will be accessible for at least 90 days. About Pfizer: Breakthrough

    2/23/26 10:00:00 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kenvue Reports Fourth Quarter and Full Year 2025 Results

    Q4 Net Sales 3.2%; Organic Sales1 1.2% Q4 Diluted EPS was $0.17; Adjusted Diluted EPS1 was $0.27 FY'25 Net Sales (2.1)%; Organic Sales (2.2)% FY'25 Diluted EPS was $0.76; Adjusted Diluted EPS was $1.08 Kenvue Inc. (NYSE:KVUE) today announced financial results for the fiscal fourth quarter and full year ended December 28, 2025. "We ended 2025 with stronger top- and bottom-line performance in the fourth quarter, which reflected both disciplined execution against our strategic priorities, as well as a more favorable year-ago comparison on sales," said Kirk Perry, Chief Executive Officer. "As we look to 2026, we remain focused on continuing to enhance our performance, while progr

    2/17/26 4:45:00 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Salesforce Announces Timing of its Fourth Quarter and Full Year Fiscal 2026 Results Conference Call

    Results to be released on February 25, 2026, after market close Salesforce (NYSE:CRM), the world's #1 AI CRM, today announced that its fourth quarter and full year fiscal 2026 results will be released on Wednesday, February 25, 2026, after the close of the market. The company will host a conference call at 2:00 p.m. (PT) / 5:00 p.m. (ET) to discuss its financial results with the investment community. A live webcast and replay of the event will be available on the Salesforce Investor Relations website at www.salesforce.com/investor. About Salesforce Salesforce helps organizations of any size become agentic enterprises — integrating humans, agents, apps, and data on a trusted, unified p

    2/4/26 4:30:00 PM ET
    $CRM
    Computer Software: Prepackaged Software
    Technology

    $CRM
    $KVUE
    $PFE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Kenvue Inc.

    SC 13G/A - Kenvue Inc. (0001944048) (Subject)

    11/14/24 1:22:40 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Salesforce Inc.

    SC 13G/A - Salesforce, Inc. (0001108524) (Subject)

    11/14/24 1:22:34 PM ET
    $CRM
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13G/A filed by Kenvue Inc.

    SC 13G/A - Kenvue Inc. (0001944048) (Subject)

    11/12/24 10:32:12 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary